A Phase I Study of PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma.
Phase of Trial: Phase I
Latest Information Update: 29 Dec 2014
At a glance
- Drugs Bortezomib (Primary) ; Interferon alpha-2b
- Indications Malignant melanoma
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 16 Aug 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 01 Jun 2012 Actual patients number is 16 as reported by ClinicalTrials.gov.